LAS VEGAS, Dec. 19, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company focused on developing innovative therapeutics in the areas of CNS, cancer, cardiovascular, and infectious diseases, is pleased to announce it has received pricing approval for ELAPRASE(r) from the Greek Ministry of Development.
